Income Tax Expense (Benefit) of NRX Pharmaceuticals, Inc. from 31 Dec 2017 to 31 Mar 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
Summary
NRX Pharmaceuticals, Inc. quarterly and annual Income Tax Expense (Benefit) in USD history and change rate from 31 Dec 2017 to 31 Mar 2025.
  • NRX Pharmaceuticals, Inc. Income Tax Expense (Benefit) for the quarter ending 31 Mar 2025 was $0.
  • NRX Pharmaceuticals, Inc. annual Income Tax Expense (Benefit) for 2024 was $0.
  • NRX Pharmaceuticals, Inc. annual Income Tax Expense (Benefit) for 2023 was $0.
  • NRX Pharmaceuticals, Inc. annual Income Tax Expense (Benefit) for 2020 was $17,841, a 79% decline from 2019.
Source SEC data
View on sec.gov
Income Tax Expense (Benefit), Trailing 12 Months (USD)
Income Tax Expense (Benefit), Quarterly (USD)
Income Tax Expense (Benefit), YoY Quarterly Change (%)
Income Tax Expense (Benefit), Annual (USD)
Income Tax Expense (Benefit), YoY Annual Change (%)

NRX Pharmaceuticals, Inc. Quarterly Income Tax Expense (Benefit) (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q1 2025 $0 $0 01 Jan 2025 31 Mar 2025 10-Q 15 May 2025 2024 Q1
Q1 2024 $0 $0 01 Jan 2024 31 Mar 2024 10-Q 15 May 2025 2024 Q1
Q1 2023 $0 $0 01 Jan 2023 31 Mar 2023 10-Q 14 May 2024 2024 Q1
Q3 2022 $0 $0 01 Jul 2022 30 Sep 2022 10-Q 14 Nov 2022 2022 Q3
Q2 2022 $0 $0 01 Apr 2022 30 Jun 2022 10-Q 15 Aug 2022 2022 Q2
Q1 2022 $0 $0 01 Jan 2022 31 Mar 2022 10-Q 16 May 2022 2022 Q1
Q3 2021 $5,356 $0 +$42,690 01 Jul 2021 30 Sep 2021 10-Q 14 Nov 2022 2022 Q3
Q2 2021 $48,046 $0 +$6,741 01 Apr 2021 30 Jun 2021 10-Q 15 Aug 2022 2022 Q2
Q1 2021 $54,787 $0 -$72,628 -100% 01 Jan 2021 31 Mar 2021 10-Q 16 May 2022 2022 Q1
Q4 2020 $17,841 $5,356 -$1,434 -37% 01 Oct 2020 31 Dec 2020 10-K/A 14 May 2021 2020 FY
Q3 2020 $19,275 $42,690 -$58,426 -371% 01 Jul 2020 30 Sep 2020 10-Q 16 Nov 2020 2020 Q3
Q2 2020 $77,701 $6,741 -$47,417 -117% 01 Apr 2020 30 Jun 2020 10-Q 14 Aug 2020 2020 Q2
Q1 2020 $125,118 $72,628 +$40,912 +129% 01 Jan 2020 31 Mar 2020 10-Q 21 May 2021 2021 Q1
Q4 2019 $84,206 $3,922 +$27,819 +88% 01 Oct 2019 31 Dec 2019 10-K/A 14 May 2021 2020 FY
Q3 2019 $56,387 $15,736 -$19,253 -55% 01 Jul 2019 30 Sep 2019 10-Q 16 Nov 2020 2020 Q3
Q2 2019 $75,640 $40,676 +$31,728 +355% 01 Apr 2019 30 Jun 2019 10-Q 14 Aug 2020 2020 Q2
Q1 2019 $43,912 $31,716 +$27,601 +671% 01 Jan 2019 31 Mar 2019 10-Q 15 May 2020 2020 Q1
Q4 2018 $16,311 $31,741 -$31,741 01 Oct 2018 31 Dec 2018 10-K 30 Mar 2020 2019 FY
Q3 2018 $48,052 $34,989 01 Jul 2018 30 Sep 2018 10-Q 14 Nov 2019 2019 Q3
Q2 2018 $8,948 01 Apr 2018 30 Jun 2018 10-Q 14 Aug 2019 2019 Q2
Q1 2018 $4,115 01 Jan 2018 31 Mar 2018 10-Q 15 May 2019 2019 Q1
Q4 2017 $0 18 Sep 2017 31 Dec 2017 10-K 15 Mar 2019 2018 FY

NRX Pharmaceuticals, Inc. Annual Income Tax Expense (Benefit) (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $0 $0 01 Jan 2024 31 Dec 2024 10-K 14 Mar 2025 2024 FY
2023 $0 01 Jan 2023 31 Dec 2023 10-K 14 Mar 2025 2024 FY
2020 $17,841 -$66,365 -79% 01 Jan 2020 31 Dec 2020 10-K/A 14 May 2021 2020 FY
2019 $84,206 +$67,895 +416% 01 Jan 2019 31 Dec 2019 10-K/A 14 May 2021 2020 FY
2018 $16,311 01 Jan 2018 31 Dec 2018 10-K 30 Mar 2020 2019 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.